Oxidative Stress of Qidan Tangshen Granules (芪丹糖肾颗粒) in Treatment of 95 Patients with Early Diabetic Kidney Disease with Qi Deficiency,Blood Stasis,and Kidney Deficiency Syndrome:A Double-Blind,Double-Simulated,Randomized Controlled Trial
|更新时间:2025-03-27
|
Oxidative Stress of Qidan Tangshen Granules (芪丹糖肾颗粒) in Treatment of 95 Patients with Early Diabetic Kidney Disease with Qi Deficiency,Blood Stasis,and Kidney Deficiency Syndrome:A Double-Blind,Double-Simulated,Randomized Controlled Trial
Journal of Traditional Chinese MedicineVol. 66, Issue 7, Pages: 695-703(2025)
ZHANG Jie,CONG Yilei,WU Tengfei,et al.Oxidative Stress of Qidan Tangshen Granules (芪丹糖肾颗粒) in Treatment of 95 Patients with Early Diabetic Kidney Disease with Qi Deficiency,Blood Stasis,and Kidney Deficiency Syndrome:A Double-Blind,Double-Simulated,Randomized Controlled Trial[J].Journal of Traditional Chinese Medicine,2025,66(07):695-703.
ZHANG Jie,CONG Yilei,WU Tengfei,et al.Oxidative Stress of Qidan Tangshen Granules (芪丹糖肾颗粒) in Treatment of 95 Patients with Early Diabetic Kidney Disease with Qi Deficiency,Blood Stasis,and Kidney Deficiency Syndrome:A Double-Blind,Double-Simulated,Randomized Controlled Trial[J].Journal of Traditional Chinese Medicine,2025,66(07):695-703.DOI: 10.13288/j.11-2166/r.2025.07.008.
Oxidative Stress of Qidan Tangshen Granules (芪丹糖肾颗粒) in Treatment of 95 Patients with Early Diabetic Kidney Disease with Qi Deficiency,Blood Stasis,and Kidney Deficiency Syndrome:A Double-Blind,Double-Simulated,Randomized Controlled Trial
(芪丹糖肾颗粒, QTG) in the treatment of early diabetic kidney disease (DKD) with
qi
deficiency, blood stasis, and kidney deficiency syndrome, and to explore its mechanism.
Methods
2
A double-blind, double-simulated method was used to enroll 200 patients with early DKD and
qi
deficiency, blood stasis, and kidney deficiency syndrome. Patients were randomly assigned in a 1∶1 ratio to the treatment group (100 cases) and the control grou
p (100 cases). The treatment group received QTG plus a valsartan capsule simulant, while the control group received valsartan capsules plus a QTG simulant, both for 12 weeks. The primary outcome was the urinary albumin-to-creatinine ratio (UACR). Secondary outcomes included estimated glomerular filtration rate (eGFR), fasting blood glucose (FBG), 2-hour postprandial blood glucose (PBG), glycated hemoglobin (HbA1c), and traditional Chinese medicine (TCM) syndrome scores (including individual symptom scores for fatigue, dull complexion, soreness and weakness of the waist and knees, headache and chest pain, irritability, spontaneous sweating, thirst and polydipsia, polyphagia, polyuria, numbness of the limbs, and the total TCM syndrome score). Oxidative stress markers including serum 8-hydroxy-2'-deoxyguanosine (8-OHDG), 3-nitrotyrosine (3-NT), and superoxide dismutase (SOD) were also assessed. Clinical efficacy and TCM syndrome efficacy were evaluated after treatment, and routine blood tests, urinalysis, and liver function tests were conducted and adverse reaction during the tria was recorded to assess safety.
Results
2
A total of 191 patients completed the study (95 in the treatment group and 96 in the control group). The treatment group showed significant reductions in UACR, FBG, PBG, and HbA1c levels after treatment (
P
<0.05 or
P
<0.01). The single TCM symptom scores except for polyphagia and total TCM syndrome scores significantly decreased (
P
<0.05 or
P
<0.01). Compared to the control group, the treatment group had signi-ficantly lower UACR, FBG, PBG levels, and total TCM syndrome scores, sinlge symptoms scores except for polyphagia and limb numbness (
P
<0.05 or
P
<0.01). Among 40 randomly selected patients (21 cases in the treatment group and 19 cases in the control group) for oxidative stress analysis, there were no significant differences in SOD, 3-NT, and 8-OHDG levels before and aft
er treatment within or between groups (
P
>0.05). The overall effective rate in the treatment group was 64.2% (61/95) and 39.6% (38/96) in the control group, while the TCM syndrome efficacy rates were 80.0% (76/95) and 24.0% (23/96), respectively, with the treatment group showing superior efficacy (
P
<0.01). No significant differences were observed in routine blood tests, urinalysis, or liver function indices before and after treatment in either group (
P
>0.05). The incidence of adverse reactions was 8.4% (8/95) in the treatment group and 9.4% (9/96) in the control group, with no statistically significant difference (
P
>0.05).
Conclusion
2
QTG can effectively reduce UACR and blood glucose levels, alleviate clinical symptoms, and improve clinical efficacy in patients with early DKD with
qi
deficiency, blood stasis, and kidney deficiency syndrome. The treatment is well-tolerated and safe, with no significant impact on oxidative stress markers.
GÓRRIZ JL , GONZÁLEZ-JUANATEY JR , FACILA L , et al . Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease [J]. Nefrologia (Engl Ed) , 2023 , 43 ( 4 ): 386 - 398 .
YANG X , HU C , WANG S , et al . Clinical efficacy and safety of Chinese herbal medicine for the treatment of patients with early diabetic nephropathy: a protocol for systematic review and meta-analysis [J]. Medicine (Baltimore) , 2020 , 99 ( 29 ): e20678 .
CHRISTENSEN E . Methodology of superiority vs. equi-valence trials and non-inferiority trials [J]. J Hepatol , 2007 , 46 ( 5 ): 947 - 954 .
ZHANG X , DING X , CAO G , et al . Efficacy and safety of valsartan in reducing blood pressure and albuminuria in Chinese patients with essential hypertension: a multicenter prospective open-label observational study [J]. Curr Med Res Opin , 2012 , 28 ( 10 ): 1677 - 1684 .
MIRANDA-DÍAZ AG , PAZARÍN-VILLASEÑOR L , YANOWSKY-ESCATELL FG , et al . Oxidative stress in diabetic nephropathy with early chronic kidney disease [J]. J Diabetes Res , 2016 , 2016 : 7047238 . doi: 10. 1155/2016/7047238 http://dx.doi.org/10.1155/2016/7047238 .
MA L , WU F , SHAO Q , et al . baicalin alleviates oxidative stress and inflammation in diabetic nephropathy via Nrf2 and MAPK signaling pathway [J]. Drug Des Devel Ther , 2021 , 15 : 3207 - 3221 . doi: 10.2147/DDDT.S319260 http://dx.doi.org/10.2147/DDDT.S319260 .
GRAILLE M , WILD P , SAUVAIN JJ , et al . Urinary 8-OHdG as a biomarker for oxidative stress: a systematic literature review and meta-analysis [J]. Int J Mol Sci , 2020 , 21 ( 11 ): 3743 .
RODRIGUES DBB , PUNARO GR , LIMA DY , et al . Cupuaçu extract protects the kidneys of diabetic rats by modulating Nrf2/NF-κB p65 and iNOS [J]. An Acad Bras Cienc , 2023 , 95 ( suppl 1 ): e20220927 .
ZHANG XG , ZHANG YQ , CHENG QP , et al . The impact of insulin pump therapy to oxidative stress in patients with diabetic nephropathy [J]. Eur J Med Res , 2018 , 23 ( 1 ): 7 .
KEHM R , RÜCKRIEMEN J , WEBER D , et al . Endogenous advanced glycation end products in pancreatic islets after short-term carbohydrate intervention in obese, diabetes-prone mice [J]. Nutr Diabetes , 2019 , 9 ( 1 ): 9 .
WU T , YANG X , CONG Y , et al . Effects of Qidantang Granule on early stage of diabetic kidney disease in rats [J]. Aging (Albany NY) , 2022 , 14 ( 11 ): 4888 - 4896 .